Research And Markets Research And Markets
0 CHECKOUT

Osteosarcoma - Pipeline Review, H1 2015

  • ID: 3266287
  • April 2015
  • 137 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Advaxis, Inc.
  • Amgen Inc.
  • Bayer AG
  • Exelixis, Inc.
  • Isofol Medical AB
  • Merck & Co., Inc.
  • MORE

Osteosarcoma - Pipeline Review, H1 2015

Summary

This, ‘Osteosarcoma - Pipeline Review, H1 2015’, provides an overview of the Osteosarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Advaxis, Inc.
  • Amgen Inc.
  • Bayer AG
  • Exelixis, Inc.
  • Isofol Medical AB
  • Merck & Co., Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Osteosarcoma Overview
Therapeutics Development
Pipeline Products for Osteosarcoma - Overview
Pipeline Products for Osteosarcoma - Comparative Analysis
Osteosarcoma - Therapeutics under Development by Companies
Osteosarcoma - Therapeutics under Investigation by Universities/Institutes
Osteosarcoma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Osteosarcoma - Products under Development by Companies
Osteosarcoma - Products under Investigation by Universities/Institutes
Osteosarcoma - Companies Involved in Therapeutics Development
Advaxis, Inc.
Amgen Inc.
Bayer AG
Bellicum Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc.
Exelixis, Inc.
Isofol Medical AB
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Neusentis
Novartis AG
Sutro Biopharma, Inc.
Osteosarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADXS-HER2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alendronate sodium + HPMA + TNP-470 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-7209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-1249 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
celyvir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
irinotecan sucrosofate liposomal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISOMC-091 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LLL-12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBC-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Target GD2 for Osteosarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radium Ra 223 dichloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Osteosarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Osteosarcoma - Recent Pipeline Updates
Osteosarcoma - Dormant Projects
Osteosarcoma - Discontinued Products
Osteosarcoma - Product Development Milestones
Featured News & Press Releases
Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting
Oct 30, 2014: Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study
May 27, 2014: Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma
Mar 17, 2014: First Cancer Trial Launched Using CAR T Cells Engineered with a Safety Switch
Oct 08, 2013: ILC Granted Orphan Drug Designation in Europe for the Treatment of Osteosarcoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Osteosarcoma, H1 2015
Number of Products under Development for Osteosarcoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Osteosarcoma - Pipeline by Advaxis, Inc., H1 2015
Osteosarcoma - Pipeline by Amgen Inc., H1 2015
Osteosarcoma - Pipeline by Bayer AG, H1 2015
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015
Osteosarcoma - Pipeline by Eleison Pharmaceuticals, Inc., H1 2015
Osteosarcoma - Pipeline by Exelixis, Inc., H1 2015
Osteosarcoma - Pipeline by Isofol Medical AB, H1 2015
Osteosarcoma - Pipeline by Merck & Co., Inc., H1 2015
Osteosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015
Osteosarcoma - Pipeline by Neusentis, H1 2015
Osteosarcoma - Pipeline by Novartis AG, H1 2015
Osteosarcoma - Pipeline by Sutro Biopharma, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Osteosarcoma Therapeutics - Recent Pipeline Updates, H1 2015
Osteosarcoma - Dormant Projects, H1 2015
Osteosarcoma - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Osteosarcoma, H1 2015
Number of Products under Development for Osteosarcoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Advaxis, Inc.
Amgen Inc.
Bayer AG
Bellicum Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc.
Exelixis, Inc.
Isofol Medical AB
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Neusentis
Novartis AG
Sutro Biopharma, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db